References
- Akanji, A. O., Ohaeri, J. U., Al-Shammri, S., & Fatania, H. R. (2009). Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Research, 169(1), 56–61. https://doi.org/https://doi.org/10.1016/j.psychres.2008.06.010
- Alhamoruni, A., Lee, A. C., Wright, K. L., Larvin, M., & O’Sullivan, S. E. (2010). Pharmacological Effects of Cannabinoids on the Caco-2 cell culture model of intestinal permeability. The Journal of Pharmacology and Experimental Therapeutics, 335(1), 92–102. https://doi.org/https://doi.org/10.1124/jpet.110.168237
- Alhamoruni, A., Wright, K. L., Larvin, M., & O’Sullivan, S. E. (2012). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability: Cannabinoids and intestinal permeability. British Journal of Pharmacology, 165(8), 2598–2610. https://doi.org/https://doi.org/10.1111/j.1476-5381.2011.01589.x
- Alshaarawy, O., & Anthony, J. C. (2015). Cannabis smoking and serum C-reactive protein: A quantile regressions approach based on NHANES 2005–2010. Drug and Alcohol Dependence, 147(1), 203–207. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2014.11.017
- Alshaarawy, O., Sidney, S., Auer, R., Green, D., Soliman, E. Z., Goff, D. C., & Anthony, J. C. (2019). Cannabis use and markers of systemic inflammation: The coronary artery risk development in young adults study. The American Journal of Medicine, 132(11), 1327–1334.e1. https://doi.org/https://doi.org/10.1016/j.amjmed.2019.04.045
- Cabral, G., & Griffin-Thomas, L. (2008). Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocrine, Metabolic & Immune Disorders Drug Targets, 8(3), 159–172. https://doi.org/https://doi.org/10.2174/187153008785700118
- Colizzi, M., Burnett, N., Costa, R., De Agostini, M., Griffin, J., & Bhattacharyya, S. (2018). Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort. Psychiatry Research, 268, 381–387. https://doi.org/https://doi.org/10.1016/j.psychres.2018.08.005
- Corsi-Zuelli, F., Marques, L., da Roza, D. L., Loureiro, C. M., Shuhama, R., Di Forti, M., Menezes, P. R., Louzada-Junior, P., & Del-Ben, C. M. (2021). The independent and combined effects of cannabis use and systemic inflammation during the early stages of psychosis: Exploring the two-hit hypothesis. Psychological Medicine, 19, 1–11. https://doi.org/https://doi.org/10.1017/S0033291721000726
- Dantzer, R., & Walker, A. K. (2014). Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? Journal of Neural Transmission, 121(8), 925–932. https://doi.org/https://doi.org/10.1007/s00702-014-1187-1
- Dickerson, F., Stallings, C., Origoni, A., Boronow, J., & Yolken, R. (2007). C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophrenia Research, 93(1–3), 261–265. https://doi.org/https://doi.org/10.1016/j.schres.2007.03.022
- Ellis, R. J., Peterson, S., Cherner, M., Morgan, E., Schrier, R., Tang, B., Hoenigl, M., Letendre, S., & Iudicello, J. (2021). Beneficial effects of cannabis on blood–Brain barrier function in human immunodeficiency virus. Clinical Infectious Diseases, 73(1), 124–129. https://doi.org/https://doi.org/10.1093/cid/ciaa437
- Ellis, R. J., Peterson, S. N., Li, Y., Schrier, R., Iudicello, J., Letendre, S., Morgan, E., Tang, B., Grant, I., & Cherner, M. (2020). Recent cannabis use in HIV is associated with reduced inflammatory markers in CSF and blood. Neurology – Neuroimmunology Neuroinflammation, 7(5), e809. https://doi.org/https://doi.org/10.1212/NXI.0000000000000809
- Ferguson, E. G., Mannes, Z. L., & Ennis, N. (2019). Is marijuana use associated with lower inflammation? Results from waves III and IV of the national longitudinal study of adolescent to adult health. Drug and Alcohol Dependence, 198, 162–167. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2019.01.021
- Gibson, C. L., Bassir Nia, A., Spriggs, S. A., DeFrancisco, D., Swift, A., Perkel, C., Zhong, X., Mazumdar, M., Fernandez, N., Patel, M., Kim-Schulze, S., & Hurd, Y. L. (2020). Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research, 293, 113380. https://doi.org/https://doi.org/10.1016/j.psychres.2020.113380
- Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry, 21(12), 1696–1709. https://doi.org/https://doi.org/10.1038/mp.2016.3
- González-Pinto, A., Mosquera, F., Palomino, A., Alberich, S., Gutiérrez, A., Haidar, K., Vega, P., Barbeito, S., Ortiz, A., & Matute, C. (2010). Increase in brainderived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. International Clinical Psychopharmacoly, 25(4), 241–245. https://doi.org/https://doi.org/10.1097/YIC.0b013e328338bc5a
- Graczyk, M., Lewandowska, A. A., & Dzierżanowski, T. (2021). The therapeutic potential of cannabis in counteracting oxidative stress and inflammation. Molecules, 26(15), 4551. https://doi.org/https://doi.org/10.3390/molecules26154551
- Guillouard, M., Authier, N., Pereira, B., Soubrier, M., & Mathieu, S. (2021). Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and metaanalysis. Rheumatology, 60(2), 549–556. https://doi.org/https://doi.org/10.1093/rheumatology/keaa534
- Haider, D. G., Leuchten, N., Schaller, G., Gouya, G., Kolodjaschna, J., Schmetterer, L., Kapiotis, S., & Wolzt, M. (2006). C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clinical and Experimental Immunology, 146(3), 533–539. https://doi.org/https://doi.org/10.1111/j.1365-2249.2006.03224.xrheumatology/keaa534
- Horsdal, H. T., Benros, M. E., Köhler-Forsberg, O., Krogh, J., & Gasse, C. (2017). Metabolic profile at first-time schizophrenia diagnosis: A population-based cross-sectional study. Neuropsychiatric Disease and Treatment, 13, 621–630. https://doi.org/https://doi.org/10.2147/NDT.S119632
- Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend, 191, 234–258. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.07.011
- Johnsen, E., Fathian, F., Kroken, R. A., Steen, V. M., Jørgensen, H. A., Gjestad, R., & Løberg, E.-M. (2016). The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry, 16, 60–60. https://doi.org/https://doi.org/10.1186/s12888-016-0769-x
- Joseph, J., Depp, C., Martin, A. S., Daly, R. E., Glorioso, D. K., Palmer, B. W., & Jeste, D. V. (2015). Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophrenia Research, 168(1–2), 456–460. https://doi.org/https://doi.org/10.1016/j.schres.2015.08.019
- Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/https://doi.org/10.1093/schbul/13.2.261
- Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015). Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. The Lancet. Psychiatry, 2(3), 258–270. https://doi.org/https://doi.org/10.1016/S2215-0366(14)00122-9
- Kimball, E. S., Schneider, C. R., Wallace, N. H., & Hornby, P. J. (2006). Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. American Journal of Physiology-Gastrointestinal and Liver Physiology, 291(2), G364–371. https://doi.org/https://doi.org/10.1152/ajpgi.00407.2005
- King, C. C., Piper, M. E., Gepner, A. D., Fiore, M. C., Baker, T. B., & Stein, J. S. (2017). Longitudinal impact of smoking and smoking cessation on inflammatory markers of cardiovascular disease risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(2), 374–379. https://doi.org/https://doi.org/10.1161/ATVBAHA.116.308728
- Klein, T. W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology, 5(5), 400–411. https://doi.org/https://doi.org/10.1038/nri1602
- Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019). Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. European Neuropsychopharmacology, 29(1), 32–45. https://doi.org/https://doi.org/10.1016/j.euroneuro.2018.11.1105
- Larsen, C., Anderson, A., Appella, E., Oppenheim, J., & Matsushima, K. (1989). The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science, 243 (4897), 1464–1466. https://doi.org/https://doi.org/10.1126/science.2648569
- Lee, A. H., Lange, C., Ricken, R., Hellweg, R., & Lang, U. E. (2011). Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. Journal of Clinical Psychopharmacology, 31(3), 334–336. https://doi.org/https://doi.org/10.1097/JCP.0b013e31821895c1
- Lowin, T., Schneider, M., & Pongratz, G. (2019). Joints for joints: Cannabinoids in the treatment of rheumatoid arthritis. Current Opinion in Rheumatology, 31(3), 271–278. https://doi.org/https://doi.org/10.1097/BOR.0000000000000590
- Lynch, M. E., & Ware, M. A. (2015). Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. Journal of Neuroimmune Pharmacology : The Official Journal of the Society on NeuroImmune Pharmacology, 10(2), 293–301. https://doi.org/https://doi.org/10.1007/s11481-015-9600-6
- Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., & Dittel, B. N. (2005). Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. Journal of Neurochemistry, 95(2), 437–445. https://doi.org/https://doi.org/10.1111/j.1471-4159.2005.03380.x
- Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N., Cuadrado, A., & de Ceballos, M. L. (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer’s disease. Molecular Pharmacology, 79(6), 964–973. https://doi.org/https://doi.org/10.1124/mol.111.071290
- Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., & Lutz, B. (2004). The endogenous cannabinoid system protects against colonic inflammation. Journal of Clinical Investigation, 113(8), 1202–1209. https://doi.org/https://doi.org/10.1172/JCI200419465
- McCoy, K. L. (2016). Interaction between cannabinoid system and toll-like receptors controls inflammation. Mediators Inflamm, 2016, 5831315. https://doi.org/https://doi.org/10.1155/2016/5831315
- McKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M., & Nagarkatti, P. S. (2002). Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther, 302(2), 451–465. https://doi.org/https://doi.org/10.1124/jpet.102.033506
- Miller, B. J., Buckley, P. F., & McEvoy, J. P. (2018). Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophrenia Research, 195, 275–282. https://doi.org/https://doi.org/10.1016/j.schres.2017.08.027
- Müller, N. (2018). Inflammation in schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophrenia Bulletin, 44(5), 973–982. https://doi.org/https://doi.org/10.1093/schbul/sby024
- Okafor, C. N., Li, M., & Paltzer, J. (2020). Self-reported cannabis use and biomarkers of inflammation among adults in the United States. Brain Behavior and Immunity – Health, 7, 100109. https://doi.org/https://doi.org/10.1016/j.bbih.2020.100109
- Olesen, J. A., Posselt, C. M., Poulsen, C. H., Nordentoft, M., & Hjorthøj, C. (2020). Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls. Psychological Medicine, 50(3), 499–506. https://doi.org/https://doi.org/10.1017/S0033291719000370
- Orsolini, L., Sarchione, F., Vellante, F., Fornaro, M., Matarazzo, I., Martinotti, G., Valchera, A., Di Nicola, M., Carano, A., Di Giannantonio, M., Perna, G., Olivieri, L., & De Berardis, D. (2018). Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Current Neuropharmacology, 16(5), 583–606. https://doi.org/https://doi.org/10.2174/1570159X16666180119144538
- Pan, S., Tan, Y., Yao, S., Zhao, X., & Xiong, J. (2016). Serum high-sensitivity C-reactive protein: A delicate sentinel elevated in drug-free acutely agitated patients with schizophrenia. Psychiatry Research, 246, 89–94. https://doi.org/https://doi.org/10.1016/j.psychres.2016.09.033
- Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., & Corsi, L. (2018). Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Research International, 2018, 1691428. https://doi.org/https://doi.org/10.1155/2018/1691428
- Pereira, S. R., Hackett, B., O'Driscoll, D. N., Sun, M. C., & Downer, E. J. (2021). Cannabidiol modulation of oxidative stress and signalling. Neuronal Signal, 5(3), NS20200080. https://doi.org/https://doi.org/10.1042/NS20200080
- Perisetti, A., Rimu, A. H., Khan, S. A., Bansal, P., & Goyal, H. (2020). Role of cannabis in inflammatory bowel diseases. Annals of Gastroenterology, 33(2), 134–144. https://doi.org/https://doi.org/10.20524/aog.2020.0452
- Reichert, V., Xue, X., Bartscherer, D., Jacobsen, D., Fardellone, C., Folan, P., Kohn, N., Talwar, A., & Metz, C. N. (2009). A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease. Chest, 136(1), 212–219. https://doi.org/https://doi.org/10.1378/chest.08-2288
- Song, C., Zhang, Y., & Dong, Y. (2013). Acute and subacute IL-1β administrations differentially modulate neuroimmune and neurotrophic systems: Possible implications for neuroprotection and neurodegeneration. J Neuroinflammation, 10, 59. https://doi.org/https://doi.org/10.1186/1742-2094-10-59
- Sproston, N. R., & Ashworth, J. J. (2018). Role of C-reactive protein at sites of inflammation and infection. Front Immunol, 9, 754. https://doi.org/https://doi.org/10.3389/fimmu.2018.00754
- Storr, M., Devlin, S., Kaplan, G. G., Panaccione, R., & Andrews, C. N. (2014). Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis, 20(3), 472–480. https://doi.org/https://doi.org/10.1097/01.MIB.0000440982.79036.d6
- Suárez-Pinilla, P., López-Gil, J., & Crespo-Facorro, B. (2014). Immune system: A possible nexus between cannabinoids and psychosis. Brain, Behavior, and Immunity, 40, 269–282. https://doi.org/https://doi.org/10.1016/j.bbi.2014.01.018
- Szabo, A., Akkouh, I. A., Ueland, T., Lagerberg, T. V., Dieset, I., Bjella, T., Aukrust, P., Le Hellard, S., Stavrum, A.-K., Melle, I., Andreassen, O. A., & Djurovic, S. (2020). Cannabis use is associated with increased levels of soluble gp130 in schizophrenia but not in bipolar disorder. Frontiers in Psychiatry, 11, 642. https://doi.org/https://doi.org/10.3389/fpsyt.2020.00642
- Tanasescu, R., & Constantinescu, C. S. (2010). Cannabinoids and the immune system: An overview. Immunobiology, 215(8), 588–597. https://doi.org/https://doi.org/10.1016/j.imbio.2009.12.005
- Wang, A. K., & Miller, B. J. (2018). Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression. Schizophrenia Bulletin, 44(1), 75–83. https://doi.org/https://doi.org/10.1093/schbul/sbx035
- Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., & Mattison, P. G. on behalf of the MUSEC Research Group. (2012). Multiple sclerosis and extract of cannabis: Results of the MUSEC trial. Journal of Neurology, Neurosurgery, and Psychiatry, 83(11), 1125–1132. https://doi.org/https://doi.org/10.1136/jnnp-2012-302468
- Zhang, X. Y., Tan, Y.-L., Chen, D.-C., Tan, S.-P., Yang, F.-D., Wu, H. E., Zunta-Soares, G. B., Huang, X.-F., Kosten, T. R., & Soares, J. C. (2016). Interaction of BDNF with cytokines in chronic schizophrenia. Brain Behavior and Immunity, 51, 169–175. https://doi.org/https://doi.org/10.1016/j.bbi.2015.09.014